Rhythm Pharmaceuticals, Inc.
RYTM
Rank in Stocks
#3069
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Share Price
$86.36
Last synced: 2026-10-16
Market Cap
$5.95B
Change (1 day)
-1.83%
Change (1 year)
-21.69%
Country
US
Trade Rhythm Pharmaceuticals, Inc. (RYTM)
Category
Healthcare
Operating Margin for Rhythm Pharmaceuticals, Inc. (RYTM)
Operating Margin as of October 2026 TTM: -83.62%
According to Rhythm Pharmaceuticals, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is -83.62%. At the end of 2023 the company had an Operating Margin of -238.10%.
Operating Margin history for Rhythm Pharmaceuticals, Inc. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -83.62% | -59.02% |
| 2024 | -204.04% | -14.30% |
| 2023 | -238.10% | -68.59% |
| 2022 | -757.92% | -85.94% |
| 2021 | -5,391.85% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.46% |
US
|
|
| -149.01% | -98.22% |
US
|
|
| 25.57% | -100.31% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.34% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.